Surrozen (SRZN) Revenue (2024 - 2026)

Surrozen (SRZN) posted quarterly Revenue of $5.0 million for Q1 2026, up 408.65% year-over-year from $983000.0 in Q1 2025, and up 846.97% quarter-over-quarter from $528000.0 in Q4 2025.

Surrozen (SRZN) Revenue (2024 - 2026) Analysis & Trends

Surrozen's Revenue history runs 3 years deep, the most recent figure standing at $5.0 million for Q1 2026.

  • In Q1 2026, Revenue rose 408.65% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $7.5 million (down 35.61% YoY), while the FY2025 annual figure was $3.5 million, down 67.37% from the prior year.
  • Revenue for Q1 2026 stood at $5.0 million, up from $528000.0 in the prior quarter.
  • The five-year high for Revenue was $10.0 million in Q3 2024, with the low at $528000.0 in Q4 2025.
  • The 3-year median for Revenue is $983000.0 (2025), against an average of $2.7 million.
  • The sharpest annual moves came in 2025 and 2026: Revenue slumped 90.17% in 2025, then soared 408.65% in 2026.
  • Surrozen's Revenue stood at $655000.0 in 2024, then dropped by 19.39% to $528000.0 in 2025, then soared by 846.97% to $5.0 million in 2026.
  • Business Quant data shows SRZN's Revenue at $5.0 million in Q1 2026, $528000.0 in Q4 2025, and $983000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 3.33 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 4.29 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 1.56 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1.71 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 3,001.92
7 Royalty Pharma 33.72 Bn 35.84 Bn - 674.14 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 1.29 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 425.49 Mn
10 Surrozen 281.63 Mn 281.63 Mn - 5.00 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 5.00 Mn
Mar 31, 2026 5.00 Mn
Dec 31, 2025 528,000.00
Sep 30, 2025 983,000.00
Jun 30, 2025 983,000.00
Mar 31, 2025 983,000.00
Dec 31, 2024 655,000.00
Sep 30, 2024 10.00 Mn